AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

• Status: Completed
• Trial end date: 2011-06-06
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether AN2728 topical ointment is a safe and effective treatment for mild-to-moderate plaque-type psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of total body surface area (BSA) excluding face, scalp, and genitals

• Willingness and ability to apply study medication as directed, comply with study instructions, and commit to attending all study visits

• Women of childbearing potential must agree to use contraception for the entire study period

Exclusion Criteria:

• Any dermatological conditions that could interfere with clinical evaluations

• Concurrent or recent use of certain topical or systemic medications without a sufficient washout period

• Significant confounding conditions as assessed by study doctor

• Participated in any other trial of an investigational drug within 30 days or participation in a research study concurrent with this study

• Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)

• Use of a beta-blocking medication (e.g., propranolol) if the dose has not been stabilized for at least 3 months

• Pregnancy or lactation